Prochlorperazine Dimaleate | CAS#84-02-6 | CAS#3450-05-3 | Dopamine (D2) Receptor Antagonist

MedKoo Cat#: 318575 | Name: Prochlorperazine Dimaleate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Prochlorperazine dimaleate is a dopamine (D2) receptor antagonist that belongs to the phenothiazine class of antipsychotic agents that are used for the antiemetic treatment of nausea and vertigo. It is also a highly potent typical antipsychotic, 10–20 times more potent than chlorpromazine. Prochlorperazine dimaleate is also used to treat migraine headaches.

Chemical Structure

Prochlorperazine Dimaleate

CAS#84-02-6 (dimaleate)

Theoretical Analysis

MedKoo Cat#: 318575

Name: Prochlorperazine Dimaleate

CAS#: 84-02-6 (dimaleate)

Chemical Formula: C28H32ClN3O8S

Exact Mass: 0.0000

Molecular Weight: 606.09

Elemental Analysis: C, 55.49; H, 5.32; Cl, 5.85; N, 6.93; O, 21.12; S, 5.29

Price and Availability

Size	Price	Availability	Quantity
5g	USD 350.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

84-02-6 (dimaleate) 58-38-8 (free base) 3450-05-3 (maleate) 3111-70-4 (mesylate) 51888-09-6 (dimesylate)

Synonym

Prochlorperazine Dimaleate; Prochlorperazine dimaleate salt; Prochlorperazine maleate; Buccastem; Prochlorperazine Edisylate; Prochlorperazine Edisylate Salt; Prochlorperazine Maleate; Salt, Prochlorperazine Edisylate;

IUPAC/Chemical Name

2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine dimaleate

InChi Key

DSKIOWHQLUWFLG-SPIKMXEPSA-N

InChi Code

InChI=1S/C20H24ClN3S.2C4H4O4/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24;2*5-3(6)1-2-4(7)8/h2-3,5-8,15H,4,9-14H2,1H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-

SMILES Code

CN1CCN(CCCN2C3=C(C=CC=C3)SC4=CC=C(Cl)C=C24)CC1.O=C(O)/C=C\C(O)=O.O=C(O)/C=C\C(O)=O

Appearance

White to light yellow crystalline powder.

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Prochlorperazine dimaleate is a dopamine (D2) receptor antagonist.

In vitro activity:

Maximal stimulation occurred at 1 mg prochlorperazine to 2 mg microsomal protein, which resulted in a 6-fold increase in activity. However, with smaller concentrations of drug, there was a time-dependent increase in the activity of UDP-glucuronosyltransferase. Sensitivity of UDP-glucuronosyltransferase to activation by UDP-N-acetylglucosamine was lost after treatment of microsomes with prochlorperazine. These results indicate that prochlorperazine causes a profound reorganization of the interactions between lipids and enzyme since the activity and allosteric properties of UDP-glucuronosyltransferase are known to depend on interactions with lipids in a gel phase. Reference: Biochem Pharmacol. 1988 Apr 1;37(7):1259-62. https://pubmed.ncbi.nlm.nih.gov/2833274/

In vivo activity:

Prochlorperazine (1-2 mg kg(-1) s.c./i.p.) produced an increase of the pain threshold in the mouse hot-plate test. The antinociception produced by prochlorperazine was prevented by the D(2) selective agonist quinpirole, the unselective muscarinic antagonist atropine, the M(1) selective antagonist pirenzepine, and by the choline uptake inhibitor hemicholinium-3 hydrobromide (HC-3). Moreover, prochlorperazine antinociception was abolished by pretreatment with an aODN against the M(1) receptor subtype, administered at the dose of 2 nmol per single i.c.v. injection. Reference: Pharmacol Res. 2004 Sep;50(3):351-8. https://pubmed.ncbi.nlm.nih.gov/15225680/

	Solvent	mg/mL	mM
Solubility
	DMSO:PBS (pH 7.2) (1:5)	0.2	0.26

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 606.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Dannenberg A, Zakim D. Effects of prochlorperazine on the function of integral membrane proteins. Biochem Pharmacol. 1988 Apr 1;37(7):1259-62. doi: 10.1016/0006-2952(88)90779-4. PMID: 2833274. 2. Liabeuf S, Stuhl-Gourmand L, Gackière F, Mancuso R, Sanchez Brualla I, Marino P, Brocard F, Vinay L. Prochlorperazine Increases KCC2 Function and Reduces Spasticity after Spinal Cord Injury. J Neurotrauma. 2017 Dec 15;34(24):3397-3406. doi: 10.1089/neu.2017.5152. Epub 2017 Sep 19. PMID: 28747093. 3. Ghelardini C, Galeotti N, Uslenghi C, Grazioli I, Bartolini A. Prochlorperazine induces central antinociception mediated by the muscarinic system. Pharmacol Res. 2004 Sep;50(3):351-8. doi: 10.1016/j.phrs.2004.02.005. PMID: 15225680.

In vitro protocol:

1. Dannenberg A, Zakim D. Effects of prochlorperazine on the function of integral membrane proteins. Biochem Pharmacol. 1988 Apr 1;37(7):1259-62. doi: 10.1016/0006-2952(88)90779-4. PMID: 2833274.

In vivo protocol:

1. Liabeuf S, Stuhl-Gourmand L, Gackière F, Mancuso R, Sanchez Brualla I, Marino P, Brocard F, Vinay L. Prochlorperazine Increases KCC2 Function and Reduces Spasticity after Spinal Cord Injury. J Neurotrauma. 2017 Dec 15;34(24):3397-3406. doi: 10.1089/neu.2017.5152. Epub 2017 Sep 19. PMID: 28747093. 2. Ghelardini C, Galeotti N, Uslenghi C, Grazioli I, Bartolini A. Prochlorperazine induces central antinociception mediated by the muscarinic system. Pharmacol Res. 2004 Sep;50(3):351-8. doi: 10.1016/j.phrs.2004.02.005. PMID: 15225680.

1: Lau Moon Lin M, Robinson PD, Flank J, Sung L, Dupuis LL. The Safety of Prochlorperazine in Children: A Systematic Review and Meta-Analysis. Drug Saf. 2016 Feb 16. [Epub ahead of print] PubMed PMID: 26884326. 2: Coralic Z, Kim AS, Vinson DR. Prochlorperazine-Induced Hemidystonia Mimicking Acute Stroke. West J Emerg Med. 2015 Jul;16(4):572-4. doi: 10.5811/westjem.2015.4.26003. Epub 2015 Jul 2. PubMed PMID: 26265971; PubMed Central PMCID: PMC4530917. 3: Yamada T, Kanazawa Y, Aoki Y, Uchida E. Incidence of nausea and vomiting induced by oxycodone administered with prochlorperazine in Japanese cancer patients. J Nippon Med Sch. 2015;82(2):100-5. doi: 10.1272/jnms.82.100. PubMed PMID: 25959201. 4: Simanjuntak Y, Liang JJ, Lee YL, Lin YL. Repurposing of prochlorperazine for use against dengue virus infection. J Infect Dis. 2015 Feb 1;211(3):394-404. doi: 10.1093/infdis/jiu377. Epub 2014 Jul 14. PubMed PMID: 25028694. 5: Patel M, Nigmatullina Y, Seemungal BM, Golding JF, Bronstein AM. Effects of prochlorperazine on normal vestibular ocular and perceptual responses: a randomised, double-blind, crossover, placebo-controlled study. Audiol Neurootol. 2014;19(2):91-6. doi: 10.1159/000357028. Epub 2013 Dec 21. PubMed PMID: 24401765. 6: Tashiro M, Naito T, Ohnishi K, Kagawa Y, Kawakami J. Impact of genetic and non-genetic factors on clinical responses to prochlorperazine in oxycodone-treated cancer patients. Clin Chim Acta. 2014 Feb 15;429:175-80. doi: 10.1016/j.cca.2013.12.011. Epub 2013 Dec 17. PubMed PMID: 24360851. 7: Smythies J, Edelstein L. The desferrioxamine-prochlorperazine coma-clue to the role of dopamine-iron recycling in the synthesis of hydrogen peroxide in the brain. Front Mol Neurosci. 2014 Aug 4;7:74. doi: 10.3389/fnmol.2014.00074. eCollection 2014. PubMed PMID: 25136292; PubMed Central PMCID: PMC4120698. 8: Hempel C, Nörenberg W, Sobottka H, Urban N, Nicke A, Fischer W, Schaefer M. The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor. Neuropharmacology. 2013 Dec;75:365-79. doi: 10.1016/j.neuropharm.2013.07.027. Epub 2013 Aug 14. PubMed PMID: 23954492. 9: Yomiya K, Takei D, Kurosawa H, Kono B. [A study on the antiemetic effect and extrapyramidal symptoms of prochlorperazine versus perospirone for the control of nausea and vomiting due to opioid introduction]. Gan To Kagaku Ryoho. 2013 Aug;40(8):1037-41. Japanese. PubMed PMID: 23986047. 10: Clayton M, Ramamoorthy A. Physical incompatibility between prochlorperazine, diclofenac and Injekt® syringe. Anaesthesia. 2013 Jul;68(7):781-2. doi: 10.1111/anae.12307. PubMed PMID: 24044397. 11: BET 1: Metoclopramide or prochlorperazine for headache in acute migraine? Emerg Med J. 2013 Jul;30(7):595-6. doi: 10.1136/emermed-2013-202853.1. Review. PubMed PMID: 23765765. 12: Tashiro M, Naito T, Kagawa Y, Kawakami J. Simultaneous determination of prochlorperazine and its metabolites in human plasma using isocratic liquid chromatography tandem mass spectrometry. Biomed Chromatogr. 2012 Jun;26(6):754-60. doi: 10.1002/bmc.1725. Epub 2011 Oct 12. PubMed PMID: 21990013. 13: Kolli CS, Xiao J, Parsons DL, Babu RJ. Microneedle assisted iontophoretic transdermal delivery of prochlorperazine edisylate. Drug Dev Ind Pharm. 2012 May;38(5):571-6. doi: 10.3109/03639045.2011.617753. Epub 2011 Oct 8. PubMed PMID: 21980925. 14: Trottier ED, Bailey B, Lucas N, Lortie A. Prochlorperazine in children with migraine: a look at its effectiveness and rate of akathisia. Am J Emerg Med. 2012 Mar;30(3):456-63. doi: 10.1016/j.ajem.2010.12.020. Epub 2011 Feb 5. PubMed PMID: 21296523. 15: Badshah A, Subhan F, Shah NH, Bukhari NI, Saeed M, Shah KU. Once daily controlled release matrix tablet of Prochlorperazine maleate: influence of Ethocel® and/or Methocel® on in vitro drug release and bioavailability. Drug Dev Ind Pharm. 2012 Feb;38(2):190-9. doi: 10.3109/03639045.2011.595416. Epub 2011 Jul 13. PubMed PMID: 21749268. 16: Musselman ME, Browning LA, Parker D Jr, Saely S. Neuroleptic malignant syndrome associated with the use of prochlorperazine in a patient with a recent history of antipsychotic-induced neuroleptic malignant syndrome. Ann Pharmacother. 2011 Nov;45(11):e61. doi: 10.1345/aph.1Q325. Epub 2011 Oct 4. PubMed PMID: 21972252. 17: Wylie G, Makrygeorgou A, Burden AD. Buccal prochlorperazine causing perioral fixed drug eruption. Clin Exp Dermatol. 2011 Aug;36(6):672-3. doi: 10.1111/j.1365-2230.2011.04020.x. PubMed PMID: 21771013. 18: Clemons A, Vasiadi M, Kempuraj D, Kourelis T, Vandoros G, Theoharides TC. Amitriptyline and prochlorperazine inhibit proinflammatory mediator release from human mast cells: possible relevance to chronic fatigue syndrome. J Clin Psychopharmacol. 2011 Jun;31(3):385-7. doi: 10.1097/JCP.0b013e3182196e50. PubMed PMID: 21532369; PubMed Central PMCID: PMC3498825. 19: Mendhekar DN, Andrade C. Prochlorperazine-induced tardive dystonia and its worsening with clozapine in a non-mentally ill patient with migraine. Ann Pharmacother. 2011 Apr;45(4):545-6. doi: 10.1345/aph.1P194. Epub 2011 Apr 12. PubMed PMID: 21487079. 20: Hoy SM, Scott LJ. Indomethacin/prochlorperazine/caffeine: a review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache. CNS Drugs. 2011 Apr;25(4):343-58. doi: 10.2165/11206740-000000000-00000. Review. PubMed PMID: 21425885.